Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Related Articles by Review for PubMed (Select 18201922)

1.

Visceral obesity and the heart.

Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP.

Int J Biochem Cell Biol. 2008;40(5):821-36. doi: 10.1016/j.biocel.2007.12.001. Epub 2007 Dec 8. Review.

PMID:
18201922
2.

Biological specificity of visceral adipose tissue and therapeutic intervention.

Perrini S, Leonardini A, Laviola L, Giorgino F.

Arch Physiol Biochem. 2008 Oct;114(4):277-86. doi: 10.1080/13813450802334752 . Review.

PMID:
18946788
3.

Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.

Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR.

Expert Rev Cardiovasc Ther. 2008 Mar;6(3):343-68. doi: 10.1586/14779072.6.3.343. Review.

PMID:
18327995
4.

The link between abdominal obesity and the metabolic syndrome.

Phillips LK, Prins JB.

Curr Hypertens Rep. 2008 Apr;10(2):156-64. Review.

PMID:
18474184
5.

Metabolic syndrome and adipose tissue: new clinical aspects and therapeutic targets.

Iannucci CV, Capoccia D, Calabria M, Leonetti F.

Curr Pharm Des. 2007;13(21):2148-68. Review.

PMID:
17627547
6.

The role of fat topology in the risk of disease.

Matsuzawa Y.

Int J Obes (Lond). 2008 Dec;32 Suppl 7:S83-92. doi: 10.1038/ijo.2008.243. Review.

PMID:
19136997
7.

Establishment of a concept of visceral fat syndrome and discovery of adiponectin.

Matsuzawa Y.

Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(2):131-41. Review.

8.

Adiponectin: a key player in obesity related disorders.

Matsuzawa Y.

Curr Pharm Des. 2010 Jun;16(17):1896-901. Review.

PMID:
20370675
9.

Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.

Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodés-Cabau J, Bertrand OF, Poirier P.

Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1039-49. doi: 10.1161/ATVBAHA.107.159228. Epub 2008 Mar 20. Review. Erratum in: Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):e151.

10.

From obesity to diabetes.

Keller U.

Int J Vitam Nutr Res. 2006 Jul;76(4):172-7. Review.

PMID:
17243079
11.

Is visceral obesity the cause of the metabolic syndrome?

Després JP.

Ann Med. 2006;38(1):52-63. Review.

PMID:
16448989
12.

[Visceral fat and metabolic syndrome: more than a simple association].

Ribeiro Filho FF, Mariosa LS, Ferreira SR, Zanella MT.

Arq Bras Endocrinol Metabol. 2006 Apr;50(2):230-8. Epub 2006 May 23. Review. Portuguese.

13.

[The role of adiponectin in pathogenesis of metabolic syndrome and cardiovascular disease].

Kozłowska A, Kowalska I.

Endokrynol Pol. 2006 Nov-Dec;57(6):626-32. Review. Polish.

PMID:
17253436
14.

Adiponectin: a key adipocytokine in metabolic syndrome.

Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P.

Clin Sci (Lond). 2006 Mar;110(3):267-78. Review.

15.

Metabolic obesity: the paradox between visceral and subcutaneous fat.

Hamdy O, Porramatikul S, Al-Ozairi E.

Curr Diabetes Rev. 2006 Nov;2(4):367-73. Review.

PMID:
18220642
16.

Pathophysiological significance of adiponectin.

Nishida M, Funahashi T, Shimomura I.

Med Mol Morphol. 2007 Jun;40(2):55-67. Epub 2007 Jun 18. Review.

PMID:
17572841
17.

Visceral adipose tissue and atherosclerosis.

Ohman MK, Wright AP, Wickenheiser KJ, Luo W, Eitzman DT.

Curr Vasc Pharmacol. 2009 Apr;7(2):169-79. Review.

PMID:
19356000
18.

Visceral obesity and the role of the somatotropic axis in the development of metabolic complications.

Franco C, Bengtsson BA, Johannsson G.

Growth Horm IGF Res. 2001 Jun;11 Suppl A:S97-102. Review.

PMID:
11527097
19.
20.

Fat as an endocrine organ: relationship to the metabolic syndrome.

Hutley L, Prins JB.

Am J Med Sci. 2005 Dec;330(6):280-9. Review.

PMID:
16355012
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk